Trials / Completed
CompletedNCT04342676
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 433 (actual)
- Sponsor
- Mansoura University · Academic / Other
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
clinical impact of LN ratio with Kras expression in colon cancer
Detailed description
LNR and K ras were evaluated with correlated with different clinicopathological parameters of the patients, PFS and OS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | k ras | K ras |
| DRUG | Panitumumab | vectibex in stage iv |
Timeline
- Start date
- 2017-03-10
- Primary completion
- 2019-08-25
- Completion
- 2019-08-26
- First posted
- 2020-04-13
- Last updated
- 2020-04-13
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04342676. Inclusion in this directory is not an endorsement.